Testing a skin cream for adults with epidermolysis bullosa
Tests ENERGI-F703EB cream against a plain cream in adults with epidermolysis bullosa.
Key facts
- Who runs it
- Energenesis Biomedical Co., Ltd.
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 24 people, planned
- Started
- 8 Oct 2026
- Expected to end
- 15 Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ENERGI-F703EB Cream
- Matched vehicle cream
- Record updated
- 5 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with epidermolysis bullosa simplex, junctional or dystrophic type. Each person needs two similar skin wounds, so one can get the study cream and the other a cream without the drug.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- EB simplex, junctional EB or dystrophic EB, confirmed by a doctor and by lab tests. You need two wounds, each 10 - 40 cm2 in size, present for ≥ 21 days and < 9 months. They must differ in size by ≤ 20% and lie ≥ 6 cm (2.4 in) apart. They cannot be on or near joints, face, scalp, groin, palms or soles.
- Earlier treatment
- No steroid creams on the wounds, and no steroids by mouth or injection, within 28 days before Visit 2. No antibiotic creams or silver products on the wounds within 14 days before Visit 2. No other study drug within 28 days before screening.
- Biomarker or test result
- The EB type must be confirmed by lab tests, such as electron microscopy or immunofluorescence studies.
Main reasons for not taking part
- Signs of infection in the chosen wounds
- Cancer now or within 2 years before Visit 2
- Known allergy to any ingredient of the creams
- Liver or kidney problems: ALT or AST > 2× ULN, total bilirubin > 1.5× ULN, or eGFR < 30 mL/min/1.73 m2
- Pregnant or breastfeeding women, or planning a pregnancy during the study
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- A subject is eligible for the study if all of the following apply:
- With either gender aged ≥ 18 years old at the Screening Visit
- Subject has clinical diagnosis and laboratory evidence of EB simplex, junctional EB, or dystrophic EB; Note: Subjects may be included if diagnostic testing confirms subtype. Acceptable diagnostic testing methods include transmission electron microscopy and immunofluorescence studies
- Potential target and target lesions can be located anywhere on the body except on or near the joints (e.g., the elbows and the ankle), face, scalp, groin, palms and soles
- Potential target lesions have been present for ≥ 21 days and < 9 months at the Screening Visit (Visit 1)
- Subject's target EB lesions in the matched target lesion pair fulfill all of the following criteria at the Baseline Visit (Visit 2):; The size of each lesion is between 10 - 40 cm2; Each lesion did not exhibit ≥ 30% reduction in size compared to the measurement taken at the Screening Visit; The two lesions have a size difference of ≤ 20%; The two lesions are separated by ≥ 6 cm apart from each other
- Subject is able and willing to follow study procedures and instructions
- Subject has signed the written informed consent form
- Male subjects must be surgically sterile or commit to the use of a highly effective method of contraception (See Appendix 1) for the duration of the study
- Female subjects are eligible only if all of the following apply:; Not pregnant with a negative serum or urine pregnancy test at the Screening Visit and at Visit 2 before randomization (test not required for females of non-childbearing potential); Not lactating; Not planning to become pregnant during the study; If of childbearing potential, commits to the use of a highly effective method of contraception for the duration of the study (See Appendix 1 for acceptable methods of contraception)
Who cannot take part
- Subject's target EB lesions in the matched target lesion pair fulfill any of the following criteria:; Have clinical signs of infection as evidenced by ongoing adverse event and/or use of topical antibiotics within 14 days prior to Visit 2; Use of topical steroidal therapy within 28 days prior to Visit 2; Use of topical silver products (e.g. silver sulfadiazine cream, colloidal silver) within 14 days prior to Visit 2
- Use of systemic steroidal therapy within 28 days prior to Visit 2 (Except for inhaled, ophthalmic, or for systemic manifestations of EB per investigator's discretion)
- Use of any other investigational drug within 28 days prior to the Screening Visit
- Subject has a current or history of malignancy within 2 years prior to Visit 2
- With known or suspected hypersensitivity to any ingredients in ENERGI-F703EB Cream or matched vehicle cream
- With any condition judged by the investigator that entering the trial may be detrimental to the subject
- With any of the following impaired hepatic or renal functions at the Screening Visit:; ALT or AST > 2× ULN; Total bilirubin > 1.5× ULN; eGFR < 30 mL/min/1.73 m2; Note: For eGFR, the CKD-EPI creatinine equation (2021) will be used: eGFR (mL/min/1.73 m2) = 142 × min (SCr/K, 1)α × max (SCr/K, 1)-1.200 × 0.9938age × (1.012 if female); where:; SCr = serum creatinine (mg/dL); K = 0.7 (females) or 0.9 (males); α = -0.241 (females) or -0.302 (males); min = indicates minimum of SCr/K or 1; max = indicates maximum of SCr /K or 1
- A subject meeting any of the exclusion criteria will be excluded from study participation:
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a phase II, intra-subject randomized, double-blind, vehicle-controlled, parallel, multicenter study to evaluate the safety and preliminary efficacy of ENERGI-F703EB Cream in subjects who are ≥ 18 years old with epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB), or dystrophic epidermolysis bullosa (DEB). In total, approximately 24 subjects will be enrolled from multiple sites in Taiwan. The study duration per subject is approximately 16 weeks; which includes a 2 to 4-week period between Visit 1 and Visit 2 for screening, an 8-week period from Visit 2 to Visit 7 for treatment, and a 4-week period from Visit 7 to Visit 9 for safety follow-up.
The 2 groups in the trial
- ENERGI-F703EB CreamExisting treatment, for comparison
- Matched vehicle creamPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II Study Evaluating the Safety and Efficacy of ENERGI-F703EB Cream in Subjects With Epidermolysis Bullosa
- Plain-language title
- Testing a skin cream for adults with epidermolysis bullosaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 5 October 2026